ObjectiveTo evaluate the clinical efficacy and safety of Xiaozhen Formula （消疹方） in preventing skin toxicity induced by epidermal growth factor receptor inhibitors （EGFRIs） in patients with EGFR-mutant non-small cell lung cancer （NSCLC）. MethodsA randomized， double-blind， placebo-controlled， multicenter clinical study was conducted. A total of 120 patients with EGFR-mutant NSCLC from seven centers were enrolled and randomly assigned to a treatment group （60 cases） or a control group （60 cases）. On the basis of EGFRI-targeted therapy， patients in the treatment group received Xiaozhen Formula granules， whereas those in the control group received Xiaozhen Formula placebo granules， both at 10 g twice daily for 4 consecutive weeks. The primary outcomes were the grading of skin toxicity evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events （NCI-CTCAE） version 5.0 and the incidence of rash. Secondary outcomes included the time to onset and time to resolution of the highest-grade rash， the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 （EORTC QLQ-C30） scores， the Hospital Anxiety and Depression Scale （HADS） scores， and disease control rate， together with safety assessments. ResultsBased on the full analysis set （FAS）， the incidence of skin toxicity in the treatment group was 18.33% （11/60）， significantly lower than 45.00% （27/60） in the control group （P＜0.01）， with the highest severity of skin toxicity in both groups was grade 2. Among patients who developed rash， the resolution rate in the treatment group was 90.91% （10/11）， higher than that 33.33% （9/27） in the control group. The median time to resolution was 15 days （95%CI： 8-17 days） in the treatment group and it was not reached in the control group； the distribution of time to resolution differed significantly between groups （P＜0.001）. After treatment， the treatment group had higher EORTC QLQ-C30 functional scale and global health status/quality-of-life scores， and lower symptom scale， single-item scores， as well as HADS-A， and HADS-D scores than the control group （P＜0.05）. In the FAS analysis， the disease control rate （DCR） was 85.0% （51/60） in the treatment group， lower than 100.0% （60/60） in the control group （P=0.003）， whereas no significant between-group difference was observed in the per-protocol set （PPS） analysis （P=0.464）. The incidence of adverse events did not differ significantly between the two groups （P＞0.05）， and no definite safety signals related to the investigational drug were observed. ConclusionXiaozhen Formula can reduce the incidence of EGFRI-induced skin toxicity， and improve the outcome of rash regression， the patients' quality of life and psychological status in EGFR-mutant NSCLC patients.

Objective To observe the value of self-made improved cone-beam CT(CBCT)fixation components for maxillofacial scanning.Methods CBCT fixation components(chin rest,temporal clamp)equipped by Planmeca ProMax 3D Mid dental panoramic X-ray system were modified to obtain improved CBCT fixation components,including improved chin rest,temporal clamp and occipital retention band.Totally 571 patients who underwent maxillofacial CBCT examinations for dental-related diseases were retrospectively enrolled,including 288 cases(group A)underwent scanning by a junior technician using original chin rest+original temporal clamp(component 1,n=78,A1 subgroup),modified chin rest+original temporal clamp(component 2,n=74,A2 subgroup),original chin rest+original temporal clamp+occipital retention band(component 3,n=68,A3 subgroup)or modified chin rest+original temporal clamp+occipital retention band(component 4,n=68,A4 subgroup),while the rest 283 cases(group B)underwent scanning by a senior using the above components,respectively,and were taken as B1(n=72),B2(n=69),B3(n=73)and B4(n=69)subgroups.The incidence of motion artifacts were compared among A2/B2,A3/B3,A4/B4 subgroups and A1/B1 subgroups.Results Compared with A1+B1 subgroups,the overall motion artifacts rate in A4+B4 subgroups decreased from 17.33％(26/150)to 8.03％(11/137)(P=0.019),while in A2+B2 subgroups(13.29％[19/143])and A3+B3 subgroups(9.93％[14/141])did not significantly decrease(P=0.337,0.067).In group A,no statistical difference of motion artifacts rate was found between A 2(17.57％[13/74])or A3(13.24％[9/68])subgroups and A1 subgroup(23.08％[18/78])(P=0.399,0.127),while the motion artifacts rate in A4 subgroup(10.29％[7/68])was lower than that in A1 subgroup(23.08％[18/78])(P=0.041).In group B,no significant difference of motion artifacts rates was found between B2,B3 or B4 subgroups(8.70％[6/69],6.85％[5/73],5.80％[4/69])and B1 subgroup(11.11％[8/72])(P=0.632,0.369,0.258).Conclusion Self-made improved CBCT fixation components could effectively secure patients' head and reduce motion artifacts in maxillofacial CBCT.

Objective To observe the value of self-made improved cone-beam CT(CBCT)fixation components for maxillofacial scanning.Methods CBCT fixation components(chin rest,temporal clamp)equipped by Planmeca ProMax 3D Mid dental panoramic X-ray system were modified to obtain improved CBCT fixation components,including improved chin rest,temporal clamp and occipital retention band.Totally 571 patients who underwent maxillofacial CBCT examinations for dental-related diseases were retrospectively enrolled,including 288 cases(group A)underwent scanning by a junior technician using original chin rest+original temporal clamp(component 1,n=78,A1 subgroup),modified chin rest+original temporal clamp(component 2,n=74,A2 subgroup),original chin rest+original temporal clamp+occipital retention band(component 3,n=68,A3 subgroup)or modified chin rest+original temporal clamp+occipital retention band(component 4,n=68,A4 subgroup),while the rest 283 cases(group B)underwent scanning by a senior using the above components,respectively,and were taken as B1(n=72),B2(n=69),B3(n=73)and B4(n=69)subgroups.The incidence of motion artifacts were compared among A2/B2,A3/B3,A4/B4 subgroups and A1/B1 subgroups.Results Compared with A1+B1 subgroups,the overall motion artifacts rate in A4+B4 subgroups decreased from 17.33％(26/150)to 8.03％(11/137)(P=0.019),while in A2+B2 subgroups(13.29％[19/143])and A3+B3 subgroups(9.93％[14/141])did not significantly decrease(P=0.337,0.067).In group A,no statistical difference of motion artifacts rate was found between A 2(17.57％[13/74])or A3(13.24％[9/68])subgroups and A1 subgroup(23.08％[18/78])(P=0.399,0.127),while the motion artifacts rate in A4 subgroup(10.29％[7/68])was lower than that in A1 subgroup(23.08％[18/78])(P=0.041).In group B,no significant difference of motion artifacts rates was found between B2,B3 or B4 subgroups(8.70％[6/69],6.85％[5/73],5.80％[4/69])and B1 subgroup(11.11％[8/72])(P=0.632,0.369,0.258).Conclusion Self-made improved CBCT fixation components could effectively secure patients' head and reduce motion artifacts in maxillofacial CBCT.

OBJECTIVES: This study investigate the clinical and imaging features of Ewing sarcoma (ES) of the jaw. METHODS: Eight cases of pathologically diagnosed ES of the jaw from January 2010 to June 2022 were included in the study. Clinical and radiological features were retrospectively analyzed. RESULTS: Among the eight cases, the mean age at onset was 29.4 years, and the male to female ratio was 7∶1. The predilecting site was the posterior part of mandible, accounting for 75% of the cases. The lesions often exhibited early numbness of the lower lip and lymphadenopathy. The main radiographic manifestation of mandibular lesions was ill-defined radiolucency, mixed with fibrous or brush-like tumor matrix, and soft tissue mass. The maxillary ES lesions mainly presented as lytic bone destruction accompanied by adjacent soft tissue mass. Periosteal ossification was rarely seen. CONCLUSIONS The clinical and imaging characteristics of ES in the jaw are helpful for its diagnosis.
Male ; Humans ; Female ; Sarcoma, Ewing/pathology* ; Retrospective Studies ; Radiography ; Mandible/pathology* ; Lip ; Bone Neoplasms

Objective:To observe the effect of rapid point pressure on clinical effect and pulmonary function of patients with chronic persistent bronchial asthma.
Methods:A total of 60 confirmed chronic persistent bronchial asthma cases were randomly allocated into two groups, 30 in each group. Cases in the treatment group were treated with rapid point pressure, 1 h for the initial treatment, and 40 min for the ensuing treatments. The treatment was done once a day for 40 d. Cases in the control group were treated with Compound Methoxyphenamine Hydrochloride Capsules, 2 capsules for each dose, 3 times a day. The treatment lasted for 7 consecutive days. A 1-year follow-up was made for both groups.
Results:After treatment, the scores of each symptom and total symptom scores for the traditional Chinese medicine (TCM) symptoms in the treatment group were significantly higher than those in the control group (P<0.05);the total effective rates in the treatment group were higher than those in the control group in each time frame; and there was a between-group statistical significance in total effective rate after 7 d of treatment (P<0.01). After 40-day treatments, there were statistical significances in the forced expiratory volume in 1 s percentage of predicted value (FEV 1%) and inspiratory capacity (IC%) in the treatment group (P<0.05); however, there were no statistical significances (P>0.05) in forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC), peak expiratory flow rate (PEF%) and maximum midexpiratory flow rate (MMEF%); and there were no statistical significances in pulmonary function parameters in the control group. In addition, as for pulmonary function parameters, there were no intra-group statistical significances in differences before and after treatment (P>0.05).
Conclusion:Rapid point pressure can alleviate patients’ TCM symptoms and improve their FEV%and IC%.